Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors

被引：0

作者：

Yasuda, Tsukasa ^{[1
]}

Ito, Takanori ^{[1
]}

Ishikawa, Takuya ^{[1
]}

Mizuno, Kazuyuki ^{[2
]}

Yamamoto, Takafumi ^{[1
]}

Yokoyama, Shinya ^{[1
]}

Yamamoto, Kenta ^{[1
]}

Imai, Norihiro ^{[1
]}

Ishizu, Yoji ^{[1
]}

Honda, Takashi ^{[1
]}

Koshiyama, Yuichi ^{[3
]}

Yasuda, Satoshi ^{[3
]}

Toyoda, Hidenori ^{[3
]}

Ando, Yuichi ^{[2
]}

Shimoyama, Yoshie ^{[4
]}

Kawashima, Hiroki ^{[1
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, 65 Tsuruma Cho,Showa Ku, Nagoya, Aichi 4668550, Japan

[2] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, 65 Tsuruma Cho,Showa Ku, Nagoya, Aichi 4668550, Japan

[3] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, 4-86 Minaminokawa, Ogaki, Gifu 5038502, Japan

[4] Nagoya Univ Hosp, Dept Pathol & Clin Labs, 65 Tsuruma Cho,Showa Ku, Nagoya, Aichi 4668550, Japan

来源：

DIGESTIVE AND LIVER DISEASE | 2025年 / 57卷 / 04期

关键词：

Drug-induced liver injury; Immune-related adverse events; Immune checkpoint inhibitor; CELL; NIVOLUMAB;

D O I：

10.1016/j.dld.2025.01.037

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Immune-related sclerosing cholangitis (irSC) induced by immune checkpoint inhibitors (ICIs) is relatively rare, and its clinical and pathological features are not well known. Aims: We aimed to compare the clinical course and pathological findings of irSC with those of non-irSC liver injury. Methods: Clinical data were retrospectively collected from 2416 patients with advanced malignancies treated with ICIs between September 2014 and October 2023. The data of patients with severe ICIinduced liver injury who underwent liver biopsy were analyzed and compared between patients with irSC and non-irSC. Results: Ninety-three (3.8 %) patients had severe ICI-induced liver injury, and 38 underwent liver biopsy. Of these, five were diagnosed with irSC. The irSC group had a significantly longer time to onset of ICIinduced liver injury and a lower rate of improvement of liver injury than did the non-irSC group (irSC, 3/5; non-irSC, 32/33). Liver biopsies revealed more moderate-to-severe pathological cholangitis in the irSC group than in the non-irSC group (irSC, n = 5/5; non-irSC, n = 16/33). Other pathological findings were similar between the two groups. Conclusion: Appropriate management of irSC requires an understanding of its characteristics of late onset and steroid resistance, and liver biopsy, in addition to imaging, may be useful for diagnosing irSC. (c) 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页码：877 / 884

页数：8

共 30 条

[1] Case Definition and Phenotype Standardization in Drug-Induced Liver Injury [J].